MedTrace Logo

Relative Bioavailability of Phase II and Phase III Formulations of AZD0530

NCT00771979 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-06-18

No results posted yet for this study

Summary

The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Conditions

  • Healthy

Interventions

DRUG

AZD0530

of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.

DRUG

AZD0530

Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.

Sponsors & Collaborators

Principal Investigators

  • Raj Chetty, MD · AstraZeneca, Clinical Pharmacology Unit, Alderley Park

  • Mary Stuart, MD · AstraZeneca,Parklands, Alderley Park

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Completion
2009-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771979 on ClinicalTrials.gov